IRIS Accounts Production v24.2.0.383 13512661 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh135126612023-03-31135126612024-03-31135126612023-04-012024-03-31135126612022-01-31135126612022-02-012023-03-31135126612023-03-3113512661ns15:EnglandWales2023-04-012024-03-3113512661ns14:PoundSterling2023-04-012024-03-3113512661ns10:Director12023-04-012024-03-3113512661ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3113512661ns10:SmallEntities2023-04-012024-03-3113512661ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3113512661ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3113512661ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3113512661ns10:FullAccounts2023-04-012024-03-3113512661ns10:Director22023-04-012024-03-3113512661ns10:RegisteredOffice2023-04-012024-03-3113512661ns5:CurrentFinancialInstruments2024-03-3113512661ns5:CurrentFinancialInstruments2023-03-3113512661ns5:ShareCapital2024-03-3113512661ns5:ShareCapital2023-03-3113512661ns5:SharePremium2024-03-3113512661ns5:SharePremium2023-03-3113512661ns5:RetainedEarningsAccumulatedLosses2024-03-3113512661ns5:RetainedEarningsAccumulatedLosses2023-03-3113512661ns5:CostValuation2023-03-3113512661ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3113512661ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3113512661ns5:RetainedEarningsAccumulatedLosses2023-03-3113512661ns5:SharePremium2023-03-3113512661ns5:RetainedEarningsAccumulatedLosses2023-04-012024-03-311351266112023-04-012024-03-31
REGISTERED NUMBER: 13512661 (England and Wales)









NEUROCHASE HOLDINGS LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024






NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


NEUROCHASE HOLDINGS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2024







DIRECTORS: Prof S S Gill
Mrs S Kane





REGISTERED OFFICE: St Brandon's House
29 Great George Street
Bristol
BS1 5QT





REGISTERED NUMBER: 13512661 (England and Wales)

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Investments 4 101 101

CURRENT ASSETS
Debtors 5 164,342 258,729
Cash at bank 1,425 -
165,767 258,729
CREDITORS
Amounts falling due within one year 6 2,098 253,378
NET CURRENT ASSETS 163,669 5,351
TOTAL ASSETS LESS CURRENT
LIABILITIES

163,770

5,452

CAPITAL AND RESERVES
Called up share capital 7 1 1
Share premium 8 200,000 -
Retained earnings 8 (36,231 ) 5,451
SHAREHOLDERS' FUNDS 163,770 5,452

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

BALANCE SHEET - continued
31 MARCH 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 20 September 2024 and were signed on its behalf by:





Mrs S Kane - Director


NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1. STATUTORY INFORMATION

Neurochase Holdings Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern
The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. In making their assessment, the directors have reviewed the balance sheet, the likely future cashflows of the business and have considered the facilities that are available to the company along with their continued support.

At the date of approving the financial statements the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and that the going concern basis of accounting remains appropriate. The directors continue to adopt the going concern basis of accounting in preparing the financial statements.

Preparation of consolidated financial statements
The financial statements contain information about Neurochase Holdings Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Significant judgements and estimates
In the application of the company's accounting policies, which are described in note 2, management is required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Investments in subsidiaries
The company has adopted the cost model in recognising and remeasuring investments in associates. Investments in associates are recognised at cost less any accumulated impairment losses.

Dividends or other distributions received from the associated company are recognised in the income statement during the period which it relates too.

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

2. ACCOUNTING POLICIES - continued

Cash & cash equivalents
Cash and cash equivalents are basic financial instruments and include cash in hand and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Financial instruments
The company has elected to apply the provisions of Section 11 "Basic Financial Instruments".
Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include trade and other debtors, loans to related companies and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the financial asset is measured at the present value of the future receipts discounted at a market rate of interest.

Basic financial liabilities
Basic financial liabilities, including trade and other creditors, loans to related companies and bank loans are initially recognised at transaction price unless the arrangement constitutes a financial transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Impairment
Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the assets cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2023 - 3 ) .

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 April 2023
and 31 March 2024 101
NET BOOK VALUE
At 31 March 2024 101
At 31 March 2023 101

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Amounts owed by group undertakings 163,215 258,729
Other debtors 1,127 -
164,342 258,729

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Amounts owed to group undertakings - 100
Taxation and social security 599 2,018
Other creditors 1,499 251,260
2,098 253,378

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

7. CALLED UP SHARE CAPITAL

Number: Class: Nominal value: £   
510 Ordinary A shares 0.001 0.51
190 Ordinary B shares 0.001 0.19
250 Ordinary C shares 0.001 0.25
50 Ordinary D shares 0.001 0.05
10 Ordinary E shares 0.001 0.01
1.01

On 6 March 2024, the company undertook a reorganisation of its share capital. The existing ordinary shares with a nominal value of £0.01 per share were subdivided into new ordinary shares with a nominal value of £0.001 per share, As a result, the number of issued shares increased, but the total nominal value of the issued share capital remained unchanged.

On 6 March 2024, the company issued 10 E Ordinary shares with a nominal value of £0.001 per share for a total consideration of £200,000. These shares were issued at a premium of £19,999.999 per share, resulting in a share premium of £199,999.99 being recognised.

8. RESERVES
Retained Share
earnings premium Totals
£    £    £   

At 1 April 2023 5,451 - 5,451
Deficit for the year (41,682 ) (41,682 )
Cash share issue - 200,000 200,000
At 31 March 2024 (36,231 ) 200,000 163,769

9. RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

10. POST BALANCE SHEET EVENTS

On 16 August 2024, subsequent to the financial year-end, Neurochase Holdings Limited completed the acquisition of the remaining share capital of Neurochase Innovations Limited and Neurochase Technologies Limited, thereby making them wholly-owned subsidiaries of Neurochase Holdings Limited.

11. ULTIMATE CONTROLLING PARTY

The controlling party is Professor Steven Gill.